Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Icecure Medical (ICCM) and Unicycive Therapeutics (UNCY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR – Research Report), Icecure Medical (ICCM – Research Report) and Unicycive Therapeutics (UNCY – Research Report) with bullish sentiments.

Arrowhead Pharmaceuticals (ARWR)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Arrowhead Pharmaceuticals today and set a price target of $90.00. The company’s shares closed last Wednesday at $27.01.

According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of -20.2% and a 26.5% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Longboard Pharmaceuticals, and Milestone Pharmaceuticals.

Currently, the analyst consensus on Arrowhead Pharmaceuticals is a Moderate Buy with an average price target of $54.00, representing a 96.6% upside. In a report issued on November 14, Chardan Capital also maintained a Buy rating on the stock with a $60.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Icecure Medical (ICCM)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Icecure Medical today and set a price target of $3.00. The company’s shares closed last Wednesday at $0.77, close to its 52-week low of $0.52.

According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -33.2% and a 21.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as OKYO Pharma Limited Sponsored ADR, Bausch + Lomb Corporation, and EyePoint Pharmaceuticals.

Currently, the analyst consensus on Icecure Medical is a Strong Buy with an average price target of $2.30.

Unicycive Therapeutics (UNCY)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Unicycive Therapeutics today and set a price target of $4.50. The company’s shares closed last Wednesday at $0.52, close to its 52-week low of $0.40.

According to TipRanks.com, Arce is a 3-star analyst with an average return of 1.3% and a 36.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Enanta Pharmaceuticals.

Currently, the analyst consensus on Unicycive Therapeutics is a Moderate Buy with an average price target of $4.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ARWR:

• Arrowhead: Plozasiran achieved mean max reductions of up to 90% in APOC3
• Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
• GSK, Arrowhead announce deal with Janssen for rights to JNJ-3989
• Bernstein keeps Underperform on Ionis, says Arrowhead’s ARO-APOC3 looks better
• Arrowhead initiated with a Neutral at Citi